CINECA IRIS Institutional Research Information System

MICHIELI, Paolo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.980
EU - Europa 902
AS - Asia 590
AF - Africa 7
SA - Sud America 3
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
Totale 3.486
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.975
CN - Cina 347
IE - Irlanda 196
IT - Italia 151
FR - Francia 106
FI - Finlandia 101
UA - Ucraina 91
SE - Svezia 86
SG - Singapore 81
KR - Corea 74
DE - Germania 50
VN - Vietnam 50
GB - Regno Unito 39
PL - Polonia 24
BE - Belgio 16
AT - Austria 12
IN - India 10
JP - Giappone 9
NL - Olanda 8
HK - Hong Kong 6
CA - Canada 5
SN - Senegal 5
BY - Bielorussia 4
GR - Grecia 4
RU - Federazione Russa 4
TH - Thailandia 3
AU - Australia 2
BR - Brasile 2
ES - Italia 2
EU - Europa 2
HU - Ungheria 2
IR - Iran 2
NG - Nigeria 2
PK - Pakistan 2
UZ - Uzbekistan 2
CH - Svizzera 1
CL - Cile 1
CZ - Repubblica Ceca 1
KZ - Kazakistan 1
LT - Lituania 1
MO - Macao, regione amministrativa speciale della Cina 1
PT - Portogallo 1
RO - Romania 1
RS - Serbia 1
TR - Turchia 1
TW - Taiwan 1
Totale 3.486
Salva come PNG Salva come JPEG
Città #
Chandler 283
Ann Arbor 237
Beijing 234
Dublin 196
Fairfield 90
Ashburn 89
Villeurbanne 81
Dearborn 80
Houston 65
Wilmington 59
Seattle 57
Princeton 56
Singapore 55
Jacksonville 52
Medford 47
Woodbridge 43
Nyköping 39
Torino 37
Dong Ket 34
Boston 33
Cambridge 32
Pisa 32
Warsaw 23
Turin 19
Guangzhou 12
Shanghai 12
Vienna 12
Brussels 11
San Diego 11
Milan 10
Des Moines 9
Nanjing 9
Redwood City 9
Boardman 8
Buffalo 8
Fremont 8
Washington 8
Norwalk 7
Hangzhou 6
Jinan 6
Kunming 6
San Mateo 6
Santa Clara 6
Seoul 6
Shenyang 6
Silver Spring 6
Falls Church 5
Hefei 5
Los Angeles 5
Nanchang 5
Napoli 5
Amsterdam 4
Dallas 4
Menlo Park 4
Phoenix 4
Somerville 4
Verona 4
Bangkok 3
Chongqing 3
Cincinnati 3
Edinburgh 3
Padova 3
Seongdong-gu 3
Abuja 2
Antwerp 2
Atlanta 2
Bhopal 2
Chennai 2
Duncan 2
Düsseldorf 2
Frederick 2
Glen Mills 2
Helsinki 2
Hirai 2
Hong Kong 2
Lachine 2
Liverpool 2
Manchester 2
Marseille 2
Nepi 2
New York 2
Quevaucamps 2
Southend 2
São Paulo 2
Tokyo 2
Uiwang 2
Upper Marlboro 2
Westervoort 2
Xian 2
Zhengzhou 2
Acton 1
Almaty 1
Ankara 1
Baotou 1
Bar Harbor 1
Belfast 1
Belgrade 1
Bethesda 1
Braunschweig 1
Brugherio 1
Totale 2.286
Salva come PNG Salva come JPEG
Nome #
Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor. 197
ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. 153
Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody 152
Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs. 138
Four individually druggable MET hotspots mediate HGF-driven tumor progression. 138
Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth 128
Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. 115
Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors 110
Depleting MET-expressing tumor cells by ADCC provides a therapeutic advantage over inhibiting HGF/MET signaling 110
Different point mutations in the met oncogene elicit distinct biological properties. 105
Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy 98
Expression and Functional Regulation of Myoglobin in Epithelial Cancers 97
Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. 94
MET(PRC) mutations in the Ron receptor result in upregulation of tyrosine kinase activity and acquisition of oncogenic potential. 87
A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met 84
Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET 80
Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody 74
An HGF-MSP chimera disassociates the trophic properties of scatter factors from their pro-invasive activity. 73
An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice 71
Prevention of hypoxia by myoglobin expression in human tumor cells promotes differentiation and inhibits metastasis 69
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. 64
Magic-factor 1, a partial agonist of Met, induces muscle hypertrophy by protecting myogenic progenitors from apoptosis 62
Targeted anticancer therapy by a recombinant monovalent antibody against the MET oncogene 61
A novel dual specificity phosphatase induced by serum stimulation and heat shock. 60
Targeting the tumor and its microenvironment by a dual-function decoy Met receptor 60
Antibody Fragments, Compositions And Uses Thereof - granted patent (USA) 59
Expression of an ATP binding mutant of PKC-delta inhibits Sis-induced transformation of NIH3T3 cells. 58
HGF-MSP chimera protects kidneys from ischemia-reperfusion injury. 54
Mutations in the met oncogene unveil a 'dual switch' mechanism controlling tyrosine kinase activity. 54
Anti C-met Antibodies - granted patent (Canada) 54
A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/CIP1. 51
A Mesenchymal-epithelial transition factor-Agonistic Antibody Accelerates Cirrhotic Liver Regeneration and Improves Mouse Survival Following Partial Hepatectomy 50
Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. 47
ANTI-MET ANTIBODIES AND USES THEREOF 42
HIGH AFFINITY BINDING SITE OF HGFR AND METHODS FOR IDENTIFICATION OF ANTAGONISTS THEREOF 40
HGF-MET AGONIST FOR USE IN THE TREATMENT OF CANCER AND COLORECTAL FIBROSIS 40
Metron factor-1 prevents liver injury without promoting tumor growth and metastasis 39
Hypoxia, angiogenesis and cancer therapy: to breathe or not to breathe? 39
Targeted therapies: Tivantinib-a cytotoxic drug in MET inhibitor's clothes? 39
Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--response. 37
New Antibody Fragments, Compositions And Uses Thereof - granted patent (Eurasian Patent Organisation) 37
New antibody fragments, compositions and uses thereof 37
RECOMBINANT PROTEINS DERIVED FROM HGF AND MSP 36
The insulin receptor substrate-1-related 4PS substrate but not the interleukin-2R gamma chain is involved in interleukin-13-mediated signal transduction. 35
METHODS FOR PROMOTING PANCREATIC ISLET CELL GROWTH 33
MAGIC-FACTOR, A PARTIAL AGONIST OF MET, ACTS AS A SAFE HEPATOTROPHIC CYTOKINE 31
New Antibody Fragments, Compositions And Uses Thereof - granted patent (Canada) 31
p53 functional impairment and high p21waf1/cip1 expression in human T-cell lymphotropic/leukemia virus type I-transformed T cells. 28
Stimulation of the platelet-derived growth factor beta receptor signaling pathway activates protein kinase C-delta. 27
Molecular cloning, sequencing, chromosomal localization and expression of mouse p21 (Waf1). 26
TaqI RFLP of the human tropomyosin gene (TPM3) involved in the generation of the TRK oncogene. 25
Induction of WAF1/CIP1 by a p53-independent pathway. 24
Inhibition of oncogene-mediated transformation by ectopic expression of p21Waf1 in NIH3T3 cells. 24
The nhance® mutation-equipped anti-met antibody argx-111 displays increased tissue penetration and anti-tumor activity in advanced cancer patients 18
Correction: Magic-Factor 1, a Partial Agonist of Met, Induces Muscle Hypertrophy by Protecting Myogenic Progenitors from Apoptosis 9
Microscope-Based Automated Quantification of Liver Fibrosis in Mice Using a Deep Learning Algorithm 9
Totale 3.613
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.402
article - articoli 0
book - libri 0
conference - conferenze 451
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.853
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020384 0 0 15 51 30 99 64 23 27 31 31 13
2020/2021378 20 8 13 21 32 18 53 15 35 46 19 98
2021/2022669 63 51 33 63 14 15 17 23 24 40 212 114
2022/2023808 85 53 17 70 62 231 71 67 83 9 44 16
2023/2024390 43 59 22 24 23 54 6 14 2 24 71 48
2024/202556 7 49 0 0 0 0 0 0 0 0 0 0
Totale 3.613